Credit Suisse Group Lowers United Therapeutics (UTHR) Price Target to $103.00

United Therapeutics (NASDAQ:UTHR) had its price target decreased by stock analysts at Credit Suisse Group from $106.00 to $103.00 in a note issued to investors on Thursday. The brokerage currently has an “underperform” rating on the biotechnology company’s stock. Credit Suisse Group’s price target would suggest a potential downside of 10.24% from the company’s previous close.

Several other research analysts have also weighed in on UTHR. HC Wainwright reissued a “hold” rating and set a $95.00 price objective on shares of United Therapeutics in a research note on Thursday, August 2nd. BidaskClub raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, October 17th. Cowen set a $106.00 price objective on shares of United Therapeutics and gave the stock a “hold” rating in a research note on Wednesday. Zacks Investment Research downgraded shares of United Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Sunday, July 15th. Finally, Barclays restated a “sell” rating and set a $100.00 target price on shares of United Therapeutics in a report on Thursday, August 2nd. Two research analysts have rated the stock with a sell rating, four have issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $137.71.

United Therapeutics stock traded up $3.89 during midday trading on Thursday, hitting $114.75. 17,619 shares of the stock were exchanged, compared to its average volume of 334,591. United Therapeutics has a 52 week low of $100.57 and a 52 week high of $152.55. The firm has a market capitalization of $5.34 billion, a price-to-earnings ratio of 10.56, a PEG ratio of 27.68 and a beta of 1.21. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.64 and a quick ratio of 4.35.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, October 31st. The biotechnology company reported $2.42 earnings per share for the quarter, missing the consensus estimate of $3.23 by ($0.81). United Therapeutics had a return on equity of 34.42% and a net margin of 40.87%. The firm had revenue of $412.70 million for the quarter, compared to the consensus estimate of $378.22 million. During the same period in the previous year, the business earned $4.69 EPS. The firm’s revenue was down 7.4% compared to the same quarter last year. As a group, analysts predict that United Therapeutics will post 14.77 EPS for the current fiscal year.

In other news, Director Richard Giltner sold 3,240 shares of United Therapeutics stock in a transaction that occurred on Thursday, August 16th. The shares were sold at an average price of $129.38, for a total value of $419,191.20. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Christopher Causey sold 810 shares of United Therapeutics stock in a transaction that occurred on Thursday, September 6th. The shares were sold at an average price of $118.00, for a total transaction of $95,580.00. Following the completion of the sale, the director now owns 3,925 shares in the company, valued at $463,150. The disclosure for this sale can be found here. Insiders have sold a total of 4,860 shares of company stock worth $611,161 over the last 90 days. Corporate insiders own 8.20% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BancorpSouth Bank raised its holdings in shares of United Therapeutics by 11.4% in the second quarter. BancorpSouth Bank now owns 3,884 shares of the biotechnology company’s stock valued at $440,000 after purchasing an additional 397 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its holdings in shares of United Therapeutics by 9.2% in the second quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 5,319 shares of the biotechnology company’s stock valued at $602,000 after purchasing an additional 446 shares during the last quarter. Retirement Systems of Alabama raised its holdings in shares of United Therapeutics by 0.8% in the second quarter. Retirement Systems of Alabama now owns 56,385 shares of the biotechnology company’s stock valued at $6,380,000 after purchasing an additional 462 shares during the last quarter. Wedbush Securities Inc. raised its holdings in shares of United Therapeutics by 13.5% in the second quarter. Wedbush Securities Inc. now owns 4,210 shares of the biotechnology company’s stock valued at $476,000 after purchasing an additional 500 shares during the last quarter. Finally, HL Financial Services LLC raised its holdings in shares of United Therapeutics by 32.1% in the second quarter. HL Financial Services LLC now owns 2,711 shares of the biotechnology company’s stock valued at $307,000 after purchasing an additional 658 shares during the last quarter. Institutional investors own 94.62% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Further Reading: Cash Flow

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply